Prima BioMed (NASDAQ:IMMP) Upgraded to Strong-Buy at Jefferies Financial Group

Posted by Stacy Sanders on Sep 17th, 2026

Jefferies Financial Group upgraded shares of Prima BioMed (NASDAQ:IMMP – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday,Zacks reports.

A number of other research analysts have also weighed in on IMMP. Maxim Group raised Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Prima BioMed in a research report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $5.50.

Check Out Our Latest Report on IMMP

Prima BioMed Stock Down 1.0%

NASDAQ IMMP opened at $0.33 on Monday. The company has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $0.57. Prima BioMed has a 12-month low of $0.29 and a 12-month high of $3.53.

Prima BioMed’s stock is going to reverse split on Monday, September 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, September 27th.

Prima BioMed (NASDAQ:IMMP – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported ($0.09) earnings per share for the quarter. The firm had revenue of $3.68 million for the quarter.

About Prima BioMed

(Get Free Report)

Prima BioMed Limited was an Australian biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its lead development program was eftilagimod alpha, also known as IMP321, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support broader immune responses. Prima BioMed evaluated the therapy in combination with existing cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.

The company conducted clinical-development activities internationally, including in Australia, Europe and the United States.